{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:03:07Z","timestamp":1793314987646,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Astra Zeneca","award":["ESR-19-20042"],"award-info":[{"award-number":["ESR-19-20042"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02796-4","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T12:07:27Z","timestamp":1748606847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of dapagliflozin on the progression of left ventricular dysfunction in type 2 diabetes mellitus: a randomized controlled trial"],"prefix":"10.1186","volume":"24","clinical-trial-number":[{"clinical-trial-number":"actrn12619001393145","registry":"10.18810\/anzctr"}],"author":[{"given":"Thomas H.","family":"Marwick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amera","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Hwee","family":"Soh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh-Georgia","family":"Sherrif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atro","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"2796_CR1","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.2337\/dci22-0014","volume":"45","author":"R Pop-Busui","year":"2022","unstructured":"Pop-Busui R, Januzzi JL, Bruemmer D, Butalia S, Green JB, Horton WB, Knight C, Levi M, Rasouli N, Richardson CR. Heart failure: an underappreciated complication of diabetes a consensus report of the American Diabetes Association. Diabetes Care. 2022;45:1670\u201390. https:\/\/doi.org\/10.2337\/dci22-0014.","journal-title":"Diabetes Care"},{"key":"2796_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jchf.2020.10.013","volume":"9","author":"A Pandey","year":"2021","unstructured":"Pandey A, Vaduganathan M, Patel KV, Ayers C, Ballantyne CM, Kosiborod MN, Carnethon M, DeFilippi C, McGuire DK, Khan SS, et al. Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes. JACC Heart Fail. 2021;9:215\u201323. https:\/\/doi.org\/10.1016\/j.jchf.2020.10.013.","journal-title":"JACC Heart Fail"},{"key":"2796_CR3","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jcmg.2017.10.023","volume":"12","author":"JW Sacre","year":"2019","unstructured":"Sacre JW, Wong C, Chan YK, Carrington MJ, Stewart S, Kingwell BA. Left ventricular dysfunction and exercise capacity trajectory: implications for subclinical heart failure staging criteria. JACC Cardiovasc Imaging. 2019;12:798\u2013806. https:\/\/doi.org\/10.1016\/j.jcmg.2017.10.023.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2796_CR4","doi-asserted-by":"publisher","first-page":"e007216","DOI":"10.1161\/CIRCOUTCOMES.120.007216","volume":"14","author":"KA Young","year":"2021","unstructured":"Young KA, Scott CG, Rodeheffer RJ, Chen HH. Progression of preclinical heart failure: a description of stage A and B heart failure in a community population. Circ Cardiovasc Qual Outcomes. 2021;14:e007216. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.120.007216.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2796_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/ejhf.1661","volume":"22","author":"S McClelland","year":"2020","unstructured":"McClelland S, Zhou S, O\u2019Connell E, Gallagher J, Ryan F, Watson CJ, Ledwidge M, McDonald K. New-onset heart failure in the STOP-HF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure. Eur J Heart Fail. 2020;22:378\u201380. https:\/\/doi.org\/10.1002\/ejhf.1661.","journal-title":"Eur J Heart Fail"},{"key":"2796_CR6","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/ejhf.2575","volume":"24","author":"P Seferovic","year":"2022","unstructured":"Seferovic P, Farmakis D, Bayes-Genis A, Ben Gal T, Bohm M, Chioncel O, Ferrari R, Filippatos G, Hill L, Jankowska E, et al. Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24:1162\u201370. https:\/\/doi.org\/10.1002\/ejhf.2575.","journal-title":"Eur J Heart Fail"},{"key":"2796_CR7","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.jcmg.2018.03.015","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang Y, Yang H, Huynh Q, Nolan M, Negishi K, Marwick TH. Diagnosis of nonischemic stage B heart failure in type 2 diabetes mellitus: optimal parameters for prediction of heart failure. JACC Cardiovasc Imaging. 2018;11:1390\u2013400. https:\/\/doi.org\/10.1016\/j.jcmg.2018.03.015.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2796_CR8","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","volume":"62","author":"M Huelsmann","year":"2013","unstructured":"Huelsmann M, Neuhold S, Resl M, Strunk G, Brath H, Francesconi C, Adlbrecht C, Prager R, Luger A, Pacher R, Clodi M. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol. 2013;62:1365\u201372. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.069.","journal-title":"J Am Coll Cardiol"},{"key":"2796_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jama.2013.7588","volume":"310","author":"M Ledwidge","year":"2013","unstructured":"Ledwidge M, Gallagher J, Conlon C, Tallon E, O\u2019Connell E, Dawkins I, Watson C, O\u2019Hanlon R, Bermingham M, Patle A, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310:66\u201374. https:\/\/doi.org\/10.1001\/jama.2013.7588.","journal-title":"JAMA"},{"key":"2796_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","volume":"71","author":"TH Marwick","year":"2018","unstructured":"Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol. 2018;71:339\u201351. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.019.","journal-title":"J Am Coll Cardiol"},{"key":"2796_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337\u201343. https:\/\/doi.org\/10.3109\/07853890109002087.","journal-title":"Ann Med"},{"key":"2796_CR12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/0002-9149(89)90496-7","volume":"64","author":"MA Hlatky","year":"1989","unstructured":"Hlatky MA, Boineau RE, Higginbotham MB, Lee KL, Mark DB, Califf RM, Cobb FR, Pryor DB. A brief self-administered questionnaire to determine functional capacity (the duke activity status index). Am J Cardiol. 1989;64:651\u20134. https:\/\/doi.org\/10.1016\/0002-9149(89)90496-7.","journal-title":"Am J Cardiol"},{"key":"2796_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","volume":"32","author":"C Mitchell","year":"2019","unstructured":"Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, Horton K, Ogunyankin KO, Palma RA, Velazquez EJ. Guidelines for Performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32:1\u201364. https:\/\/doi.org\/10.1016\/j.echo.2018.06.004.","journal-title":"J Am Soc Echocardiogr"},{"key":"2796_CR14","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.jcmg.2019.03.032","volume":"12","author":"FA Flachskampf","year":"2019","unstructured":"Flachskampf FA, Blankstein R, Grayburn PA, Kramer CM, Kwong RYK, Marwick TH, Nagel E, Sengupta PP, Zoghbi WA, Chandrashekhar Y. Global longitudinal shortening: a positive step towards reducing confusion surrounding global longitudinal strain. JACC Cardiovasc Imaging. 2019;12:1566\u20137. https:\/\/doi.org\/10.1016\/j.jcmg.2019.03.032.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2796_CR15","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.jacc.2017.07.792","volume":"70","author":"L Ernande","year":"2017","unstructured":"Ernande L, Audureau E, Jellis CL, Bergerot C, Henegar C, Sawaki D, Czibik G, Volpi C, Canoui-Poitrine F, Thibault H, et al. Clinical implications of echocardiographic phenotypes of patients with diabetes mellitus. J Am Coll Cardiol. 2017;70:1704\u201316. https:\/\/doi.org\/10.1016\/j.jacc.2017.07.792.","journal-title":"J Am Coll Cardiol"},{"key":"2796_CR16","doi-asserted-by":"crossref","unstructured":"Anon. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111\u2013117.","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"2796_CR17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1183\/09031936.00194909","volume":"37","author":"C Casanova","year":"2011","unstructured":"Casanova C, Celli BR, Barria P, Casas A, Cote C, de Torres JP, Jardim J, Lopez MV, Marin JM, Montes de Oca M, et al. The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur Respir J. 2011;37:150.","journal-title":"Eur Respir J"},{"key":"2796_CR18","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/ejhf.643","volume":"18","author":"H Yang","year":"2016","unstructured":"Yang H, Negishi K, Wang Y, Nolan M, Saito M, Marwick TH. Echocardiographic screening for non-ischaemic stage B heart failure in the community. Eur J Heart Fail. 2016;18:1331\u20139. https:\/\/doi.org\/10.1002\/ejhf.643.","journal-title":"Eur J Heart Fail"},{"key":"2796_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jacc.2014.10.044","volume":"65","author":"W Kosmala","year":"2015","unstructured":"Kosmala W, Jellis CL, Marwick TH. Exercise limitation associated with asymptomatic left ventricular impairment: analogy with stage B heart failure. J Am Coll Cardiol. 2015;65:257\u201366. https:\/\/doi.org\/10.1016\/j.jacc.2014.10.044.","journal-title":"J Am Coll Cardiol"},{"key":"2796_CR20","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.amjmed.2023.04.035","volume":"137","author":"JW Ostrominski","year":"2024","unstructured":"Ostrominski JW, Vaduganathan M. Chapter 2: clinical and mechanistic potential of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction. Am J Med. 2024;137:S9\u201324. https:\/\/doi.org\/10.1016\/j.amjmed.2023.04.035.","journal-title":"Am J Med"},{"key":"2796_CR21","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/ehjci\/jew135","volume":"18","author":"W Kosmala","year":"2017","unstructured":"Kosmala W, Przewlocka-Kosmala M, Sharman JE, Schultz MG, Marwick TH. Stability of left ventricular longitudinal and circumferential deformation over time and standard loading conditions. Eur Heart J Cardiovasc Imaging. 2017;18:1001\u20137. https:\/\/doi.org\/10.1093\/ehjci\/jew135.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2796_CR22","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1161\/CIRCULATIONAHA.122.062021","volume":"147","author":"MJ Hundertmark","year":"2023","unstructured":"Hundertmark MJ, Adler A, Antoniades C, Coleman R, Griffin JL, Holman RR, Lamlum H, Lee J, Massey D, Miller J, et al. Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, Controlled EMPA-VISION trial. Circulation. 2023;147:1654\u201369. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062021.","journal-title":"Circulation"},{"key":"2796_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ahj.2024.08.004","volume":"277","author":"CH Soh","year":"2024","unstructured":"Soh CH, Wright L, Baumann A, Seidel B, Yu C, Nolan M, Mylius T, Marwick TH, Echo investigators in Tasmania WNSWNVWAWQ, Northern Territory A. Use of artificial intelligence-guided echocardiography to detect cardiac dysfunction and heart valve disease in rural and remote areas: rationale and design of the AGILE-echo trial. Am Heart J. 2024;277:11\u20139. https:\/\/doi.org\/10.1016\/j.ahj.2024.08.004.","journal-title":"Am Heart J"},{"key":"2796_CR24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jcmg.2016.06.012","volume":"10","author":"T Negishi","year":"2017","unstructured":"Negishi T, Negishi K, Thavendiranathan P, Cho GY, Popescu BA, Vinereanu D, Kurosawa K, Penicka M, Marwick TH, Investigators S. Effect of experience and training on the concordance and precision of strain measurements. JACC Cardiovasc Imaging. 2017;10:518\u201322. https:\/\/doi.org\/10.1016\/j.jcmg.2016.06.012.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2796_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jchf.2023.06.014","volume":"12","author":"E Potter","year":"2024","unstructured":"Potter E, Huynh Q, Haji K, Wong C, Yang H, Wright L, Marwick TH. Use of clinical and echocardiographic evaluation to assess the risk of heart failure. JACC Heart Fail. 2024;12:275\u201386. https:\/\/doi.org\/10.1016\/j.jchf.2023.06.014.","journal-title":"JACC Heart Fail"},{"key":"2796_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-024-02141-1","volume":"23","author":"CH Soh","year":"2024","unstructured":"Soh CH, de Sa AGC, Potter E, Halabi A, Ascher DB, Marwick TH. Use of the energy waveform electrocardiogram to detect subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2024;23:91. https:\/\/doi.org\/10.1186\/s12933-024-02141-1.","journal-title":"Cardiovasc Diabetol"},{"key":"2796_CR27","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"key":"2796_CR28","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jacc.2016.07.763","volume":"68","author":"W Kosmala","year":"2016","unstructured":"Kosmala W, Rojek A, Przewlocka-Kosmala M, Wright L, Mysiak A, Marwick TH. Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2016;68:1823\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2016.07.763.","journal-title":"J Am Coll Cardiol"},{"key":"2796_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jcmg.2016.11.015","volume":"10","author":"H Yang","year":"2017","unstructured":"Yang H, Negishi K, Wang Y, Nolan M, Marwick TH. Imaging-guided cardioprotective treatment in a community elderly population of stage B heart failure. JACC Cardiovasc Imaging. 2017;10:217\u201326. https:\/\/doi.org\/10.1016\/j.jcmg.2016.11.015.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2796_CR30","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/ejhf.2428","volume":"24","author":"E Potter","year":"2022","unstructured":"Potter E, Stephenson G, Harris J, Wright L, Marwick TH. Screening-guided spironolactone treatment of subclinical left ventricular dysfunction for heart failure prevention in at-risk patients. Eur J Heart Fail. 2022;24:620\u201330. https:\/\/doi.org\/10.1002\/ejhf.2428.","journal-title":"Eur J Heart Fail"},{"key":"2796_CR31","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","volume":"4","author":"W Kosmala","year":"2011","unstructured":"Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O\u2019Moore-Sullivan T, Marwick TH. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging. 2011;4:1239\u201349. https:\/\/doi.org\/10.1016\/j.jcmg.2011.08.014.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2796_CR32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-020-01100-w","volume":"19","author":"A Halabi","year":"2020","unstructured":"Halabi A, Sen J, Huynh Q, Marwick TH. Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. Cardiovasc Diabetol. 2020;19:124. https:\/\/doi.org\/10.1186\/s12933-020-01100-w.","journal-title":"Cardiovasc Diabetol"},{"key":"2796_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","volume":"5","author":"KM Talha","year":"2023","unstructured":"Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in heart failure: a review of current evidence. Int J Heart Fail. 2023;5:82\u201390. https:\/\/doi.org\/10.36628\/ijhf.2022.0030.","journal-title":"Int J Heart Fail"},{"key":"2796_CR34","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e263\u2013421. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.012.","journal-title":"J Am Coll Cardiol"},{"key":"2796_CR35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"key":"2796_CR36","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"key":"2796_CR37","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"key":"2796_CR38","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"key":"2796_CR39","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286.","journal-title":"N Engl J Med"},{"key":"2796_CR40","doi-asserted-by":"publisher","first-page":"106243","DOI":"10.1016\/j.phrs.2022.106243","volume":"180","author":"P Theofilis","year":"2022","unstructured":"Theofilis P, Antonopoulos AS, Katsimichas T, Oikonomou E, Siasos G, Aggeli C, Tsioufis K, Tousoulis D. The impact of SGLT2 inhibition on imaging markers of cardiac function: a systematic review and meta-analysis. Pharmacol Res. 2022;180:106243. https:\/\/doi.org\/10.1016\/j.phrs.2022.106243.","journal-title":"Pharmacol Res"},{"key":"2796_CR41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12933-020-01042-3","volume":"19","author":"IC Hwang","year":"2020","unstructured":"Hwang IC, Cho GY, Yoon YE, Park JJ, Park JB, Lee SP, Kim HK, Kim YJ, Sohn DW. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients. Cardiovasc Diabetol. 2020;19:69. https:\/\/doi.org\/10.1186\/s12933-020-01042-3.","journal-title":"Cardiovasc Diabetol"},{"key":"2796_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12933-020-01209-y","volume":"20","author":"YW Yu","year":"2021","unstructured":"Yu YW, Zhao XM, Wang YH, Zhou Q, Huang Y, Zhai M, Zhang J. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. Cardiovasc Diabetol. 2021;20:25. https:\/\/doi.org\/10.1186\/s12933-020-01209-y.","journal-title":"Cardiovasc Diabetol"},{"key":"2796_CR43","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12933-022-01618-1","volume":"21","author":"L Nesti","year":"2022","unstructured":"Nesti L, Pugliese NR, Sciuto P, et al. Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial. Cardiovasc Diabetol. 2022;21:181. https:\/\/doi.org\/10.1186\/s12933-022-01618-1.","journal-title":"Cardiovasc Diabetol"},{"key":"2796_CR44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12933-020-01109-1","volume":"19","author":"L Nesti","year":"2020","unstructured":"Nesti L, Pugliese NR, Sciuto P, Natali A. Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach. Cardiovasc Diabetol. 2020;19:134. https:\/\/doi.org\/10.1186\/s12933-020-01109-1.","journal-title":"Cardiovasc Diabetol"},{"key":"2796_CR45","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1034\/j.1399-3003.1999.14b06.x","volume":"14","author":"T Troosters","year":"1999","unstructured":"Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J. 1999;14:270\u20134. https:\/\/doi.org\/10.1034\/j.1399-3003.1999.14b06.x.","journal-title":"Eur Respir J"},{"key":"2796_CR46","doi-asserted-by":"publisher","first-page":"e007564","DOI":"10.1161\/CIRCHEARTFAILURE.120.007564","volume":"14","author":"SS Jain","year":"2021","unstructured":"Jain SS, Cohen DJ, Zhang Z, Uriel N, Sayer G, Lindenfeld J, Abraham WT, Mack MJ, Stone GW, Arnold SV. Defining a clinically important change in 6-minute walk distance in patients with heart failure and mitral valve disease. Circ Heart Fail. 2021;14:e007564. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.007564.","journal-title":"Circ Heart Fail"},{"key":"2796_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/01823246-201324030-00004","volume":"24","author":"MJ Shoemaker","year":"2013","unstructured":"Shoemaker MJ, Curtis AB, Vangsnes E, Dickinson MG. Clinically meaningful change estimates for the six-minute walk test and daily activity in individuals with chronic heart failure. Cardiopulm Phys Ther J. 2013;24:21\u20139.","journal-title":"Cardiopulm Phys Ther J"},{"key":"2796_CR48","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-021-01314-6","volume":"20","author":"L Nesti","year":"2021","unstructured":"Nesti L, Pugliese NR, Sciuto P, De Biase N, Mazzola M, Fabiani I, Trico D, Masi S, Natali A. Mechanisms of reduced peak oxygen consumption in subjects with uncomplicated type 2 diabetes. Cardiovasc Diabetol. 2021;20:124. https:\/\/doi.org\/10.1186\/s12933-021-01314-6.","journal-title":"Cardiovasc Diabetol"},{"key":"2796_CR49","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1177\/2047487313482283","volume":"21","author":"G Deboeck","year":"2014","unstructured":"Deboeck G, Van Muylem A, Vachiery JL, Naeije R. Physiological response to the 6-minute walk test in chronic heart failure patients versus healthy control subjects. Eur J Prev Cardiol. 2014;21:997\u20131003. https:\/\/doi.org\/10.1177\/2047487313482283.","journal-title":"Eur J Prev Cardiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02796-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T12:07:29Z","timestamp":1748606849000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02796-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2796"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02796-4","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}